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A B S T R A C T
The apicomplexan parasite Sarcocystis neurona is the primary etiologic agent of equine protozoal myeloence-
phalitis (EPM), a serious neurologic disease of horses. Many horses in the U.S. are at risk of developing EPM;
approximately 50% of all horses in the U.S. have been exposed to S. neurona and treatments for EPM are 60–70%
effective. Advancement of treatment requires new technology to identify new drugs for EPM. To address this
critical need, we developed, validated, and implemented a high-throughput screen to test 725 FDA-approved
compounds from the NIH clinical collections library for anti-S. neurona activity. Our screen identified 18
compounds with confirmed inhibitory activity against S. neurona growth, including compounds active in the nM
concentration range. Many identified inhibitory compounds have well-defined mechanisms of action, making
them useful tools to study parasite biology in addition to being potential therapeutic agents. In comparing the
activity of inhibitory compounds identified by our screen to that of other screens against other apicomplexan
parasites, we found that most compounds (15/18; 83%) have activity against one or more related apicom-
plexans. Interestingly, nearly half (44%; 8/18) of the inhibitory compounds have reported activity against do-
pamine receptors. We also found that dantrolene, a compound already formulated for horses with a peak plasma
concentration of 37.8 ± 12.8 ng/ml after 500mg dose, inhibits S. neurona parasites at low concentrations
(0.065 μM [0.036–0.12; 95% CI] or 21.9 ng/ml [12.1–40.3; 95% CI]). These studies demonstrate the use of a
new tool for discovering new chemotherapeutic agents for EPM and potentially providing new reagents to
elucidate biologic pathways required for successful S. neurona infection.
1. Introduction
The apicomplexan parasite Sarcocystis neurona is the primary etio-
logic agent of equine protozoal myeloencephalitis (EPM) (Dubey et al.,
1991). In addition to causing progressive neurologic disease in horses,
S. neurona has also been known to cause encephalitis in Pacific harbor
seals (Phoca vitulina richardsi), sea otters (Enhydra lutis), Pacific harbor
porpoises (Phocoena phocoena), California sea lions (Zalophus cali-
fornianus) and other marine mammals (Lapointe et al., 1998; Lindsay
et al., 2001b; Miller et al., 2001; Carlson-Bremer et al., 2012; Barbosa
et al., 2015). S. neurona encephalitis has also been reported in other
domestic and wild animals including, but not limited to: cats, dogs,
raccoons, minks, ferrets, fishers, lynxes and skunks (Dubey et al., 2015).
S. neurona has a complex life cycle which utilizes both a definitive
host and an intermediate host. The only known definitive hosts of S.
neurona are the North and South American opossums (Didelphis vir-
giniana and Didelphis albiventris, respectively) (Fenger et al., 1995;
Dubey et al., 2001a). Intermediate hosts of S. neurona are defined as
hosts in which mature sarcocysts, or tissue cysts, have been demon-
strated and are a source of infection for definitive hosts. Proven inter-
mediate hosts of S. neurona include: cats (Turay et al., 2002), skunks
(Cheadle et al., 2001b), raccoons (Lindsay et al., 2001a), sea otters
(Dubey et al., 2001c) and armadillos (Cheadle et al., 2001a). Sexual
reproduction of the parasite in the intestinal epithelium of the opossum
results in development of infectious sporocysts, that are released into
the environment via feces. As strict herbivores, horses become infected
by ingesting S. neurona sarcocysts present on contaminated pasture and
feed. Horses are considered aberrant hosts since tissue cyst formation
has not been commonly observed in these animals (Dubey et al.,
2001b). While details of infection and pathogenesis in horses is still
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poorly understood, it is generally accepted that progressive neurologic
disease develops when the parasites gain access to the central nervous
system where they cause inflammation and nerve cell death.
Historically, horses suspected to be infected and displaying clinical
signs compatible with S. neurona were treated with the traditional anti-
protozoal drug pyrimethamine in combination with sulfadiazine. These
compounds work synergistically and specifically to inhibit parasite folic
acid metabolism and nucleotide biosynthesis which are necessary for
parasite replication. However, the success rate with the FDA-approved
formulation of pyrimethamine and sulfadiazine treatment of EPM has
been estimated to be 60%–70% and the relapse rate to be 10% (Reed
and Saville, 1996). After in vitro cultivation of S. neurona parasites was
achieved in 1991 testing of potential therapeutic compounds became
possible (Dubey et al., 1991). Since then, several additional compounds
have been used in the treatment of EPM including: diclazuril, ponazuril,
nitazoxanide and decoquinate (Dirikolu et al., 1999, 2006; MacKay
et al., 2000; Mitchell et al., 2005; Lindsay et al., 2013). Both diclazuril
and ponazuril are FDA-approved benzeneacetonitrile compounds re-
lated to the herbicide atrazine and are hypothesized to act by inhibiting
the apicoplast (a derived non-photosynthetic plastid found in most
apicomplexa) and/or mitochondrial function in the parasite (Mitchell
et al., 2005). Nitazoxanide, an antiparasitic compound with broad ac-
tivity against protozoa, nematodes, and bacterial pathogens (Dubreuil
et al., 1996; Megraud et al., 1998; Theodos et al., 1998), exhibited in
vitro activity against S. neurona, but was removed from the EPM-treat-
ment market for health concerns related to adverse side effects (Gargala
et al., 2009). The antiprotozoal compound decoquinate disrupts elec-
tron transport in the mitochondrial cytochrome system of apicom-
plexans (Nam et al., 2011) and is commonly used to treat coccidiosis in
livestock. Recently, decoquinate was determined to have activity
against S. neurona at low concentrations in vitro (Lindsay et al., 2013).
Treatment of EPM using decoquinate in combination with the im-
munomodulator levamisole has been reported to provide significant
clinical improvement after 10 days of treatment (Ellison and Lindsay,
2012). However, concerns about this study have been raised (including
case selection, clinical assessment, and the diagnostic standards) and
additional research using confirmed EPM cases needs to be performed
to support the reported efficacy of this therapy (Dubey et al., 2015).
Methods for drug discovery for EPM are lagging behind current
technologies. Traditionally, inhibitory effects of compounds against S.
neurona were measured by in vitro merozoite production assays pat-
terned after an assay developed by Lindsay and Dubey in 2000 (Lindsay
and Dubey, 2000). These time-consuming and labor-intensive assays
were used to characterize the in vitro antiprotozoal activity of the cur-
rently available EPM drugs and other compounds against S. neurona
(Lindsay and Dubey, 1999, 2000; Lindsay et al., 2000; Gargala et al.,
2005, 2009; Dirikolu et al., 2013; Lindsay et al., 2013). Other studies
used 3H-uracil incorporation (Marsh et al., 2001), plaque assay
(Kruttlin et al., 2001), or light microscopy and TEM (Mitchell et al.,
2005) to describe the inhibitory effects of drugs on S. neurona. In recent
years, advances in molecular tools (e.g., stable transfection of S. neu-
rona) and technology have made it possible to readily screen selective
compounds or compound libraries for antiprotozoal activity (Gaji et al.,
2006; Dangoudoubiyam et al., 2014; Ojo et al., 2016). In contrast to
merozoite production assays, high-throughput screening (HTS) using
transgenic parasites is a quick and effective method for identifying in-
hibitory drug compounds and important drug targets. Recent HTS of
drug repurposing libraries against luciferase-expressing Toxoplasma
gondii, a related apicomplexan parasite, demonstrated that HTS
methods are robust and reproducible processes for identifying in-
hibitory compounds (Jin et al., 2009; Kamau et al., 2012).
The objective of this work was to identify antiprotozoal compounds
with activity against S. neurona using a HTS procedure. By screening the
NIH Clinical Collection library against luciferase-expressing S. neurona,
we identified many FDA-approved compounds that inhibit S. neurona.
2. Methods
2.1. Parasite cultures
Sarcocystis neurona strain SN-UCD1 (a generous gift from Patricia
Conrad, University of California – Davis of unknown passage number)
was passaged in bovine turbinate cells (BT cells, ATCC CRL-1390,
American Type Culture Collection, USA) in RPMI 1640 medium sup-
plemented with HEPES, 10% (v/v) fetal bovine serum, 2mM L-gluta-
mine, 50 U/ml penicillin, and 50 μg/ml streptomycin. Parasite cultures
were maintained by transferring approximately 100 μl of supernatant
from infected BT monolayers to fresh BT monolayers. Cell and parasite
cultures were incubated in a humidified chamber at 37 °C and 5% CO2.
S. neurona SN-UCD1 merozoites were harvested from infected flasks by
repeated passage through a 22-gauge needle as described previously
(Marsh et al., 1998).
2.2. Generation of GFP- and FLUC-expressing S. neurona merozoites
S. neurona merozoites expressing the reporter enzymes GFP and
firefly luciferase (FLUC) were generated using a standard electropora-
tion method described previously (Soldati and Boothroyd, 1993).
Briefly, approximately 1.0× 107 freshly lysed S. neurona merozoites
were washed twice in phosphate-buffered saline, resuspended in Cy-
tomix buffer (10mM KPO4, 120mM KCl, 0.15mM CaCl2, 5 mM MgCl2,
25mM HEPES, 2mM EDTA) and combined with 25 μg of pGRA2-GFP/
pTUB1-FLUC plasmid (Kim et al., 2007) linearized with NotI (plasmid
generously provided by J. Boothroyd, Stanford University). Electro-
poration was conducted in a 2-mm gap cuvette at 1.4 kV, 50Ω using a
Gene Pulser Xcell™ electroporation system (Bio-Rad, USA). After elec-
troporation, transfected parasites were transferred to a confluent
monolayer of host cells and incubated at 37 °C and 5% CO2. After for-
mation of GFP-positive parasite plaques (approximately 3 days post
transfection), stably transfected parasites expressing reporter genes
randomly inserted into the genome were isolated by fluorescence-ac-
tivated cell sorting (FACS), cloned by two rounds of limiting dilution,
and passaged three times as described previously before being used for
in vitro studies. Intracellular transgenic parasites infecting BT cells in a
35-mm glass-bottom dish 4 DPI were imaged with Leica TCS SP8 X
Confocal Microscope. Host and parasite nuclei were visualized using
NucBlue™ Live ReadyProbes™ Reagent (Thermo Fisher Scientific, USA).
2.3. Development and validation of HTS method
To determine the optimal parasite concentration, incubation time,
and inhibition by positive control drug pyrimethamine for the HTS, the
growth of FLUC-expressing S. neurona merozoites was evaluated. A
standard curve was constructed to determine the relationship between
FLUC activity measurement and total parasite count. Serial dilutions of
S. neurona + GFP/FLUC parasites (36 dilutions ranging from 100 to
8.4 × 105 parasites per well in triplicate) were used to infect BT cells in
96-well, tissue-culture treated, white, optically clear bottom microtiter
assay plates. FLUC activity was measured 2 h after infection using the
Bright-Glo™ Luciferase Assay System (Promega, USA) following man-
ufacturer's directions. Controls included uninfected host cells, and
media only for background subtraction. To examine the growth rate of
S. neurona + GFP/FLUC parasites, BT cells were infected with
5.0 × 103 to 2.0× 104 merozoites per well. The assay plates were
incubated at 37 °C and 5% CO2 for 8 days, allowing for approximately 2
rounds of parasite replication as approximately 3 days post infection
(DPI) are required to complete one round of asexual replication
(Lindsay et al., 1999). FLUC activity was measured every 24 h as de-
scribed previously. Uninfected BT cells were run in parallel as a nega-
tive control.
To prepare a positive control for the HTS, the inhibition efficacy of
the antiprotozoal drug pyrimethamine was verified by measuring FLUC
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activity of wells of assay plates infected with 2.0×104 S.
neurona+ GFP/FLUC parasites treated with 10 μM pyrimethamine, a
concentration reported to be 95% inhibitory (Lindsay and Dubey,
1999), in 0.1% dimethyl sulfoxide (DMSO). FLUC activity was mea-
sured as described previously every 2 days for 10 days with infected BT
cells treated with 0.1% DMSO as a negative control. The efficacy of
pyrimethamine in this assay was confirmed by treating BT cells infected
with 2.0×104 S. neurona+ GFP/FLUC parasites with various con-
centrations of pyrimethamine (50, 45, 40, 35, 30, 25, 20, 15, 10, 5, 2.5,
1.25, 0.625, and 0.5 μM) or DMSO carrier control. FLUC activity was
measured as described 4 DPI. Inhibition of S. neurona + GPF/FLUC
parasites by pyrimethamine was calculated by comparing FLUC activity
of treated and untreated parasites using equation (1).
=
−
×
=
− −
−
% inhibition
μ μ
μ
100%; μ
mean FLUC activity
DMSO treated Compound treated
DMSO treated
(1)
Estimation of the half-maximal effective concentration (EC50) for
pyrimethamine against S. neurona+ GFP/FLUC parasite growth was
estimated using a four-parametric logistic function of GraphPad Prism
7.00 Software (GraphPad, USA).
To evaluate the ability of the growth assay to identify infected cells
treated with a S. neurona inhibitor from untreated infected cells, BT
cells in 96 well plates were infected with 2.0× 104 parasites/well and
randomly treated with either 10 μM pyrimethamine (n=12) or 0.1%
DMSO (n= 60). Three separate assay plates prepared independently
were incubated at 37 °C and 5% CO2 for 4 days before FLUC activity
was measured as described previously. The robustness of the HTS
method was determined by calculating the Z′-factor, as described by
Zhang et al. (1999) using equation (2), for each assay.
= −
+
−
=
=
Z 1 (3·σ 3·σ )
μ μ
; σ std. dev, μ
mean FLUC activity
' infected uninfected
infected infected
(2)
2.4. High-throughput screen of chemical compounds
Compounds from the NIH Clinical Collection (NCC) library, pro-
vided by the National Institutes of Health Molecular Libraries Roadmap
Initiative (obtained through Evotec, San Francisco, CA) were received
as 10mM solutions in 100% DMSO. The 725 compounds were diluted
1:1000 in culture medium before being added to assay plates giving a
final compound concentration of 10 μM in 0.1% DMSO. Controls on
each assay plate included wells containing 0.1% DMSO as a negative
control, 10 μM pyrimethamine in 0.1% DMSO as a positive control, and
uninfected host cells treated with 0.1% DMSO for FLUC activity back-
ground measurement. FLUC activity was measured 4 days post-infec-
tion. The NCC library was screened twice on different days using se-
parate parasite preparations. The percent inhibition of S.
neurona + GPF/FLUC parasites for each compound was calculated
using equation (1). Compounds that demonstrated greater than 80%
inhibition of parasite growth in either screen were classified as hits and
selected for secondary confirmational screening.
2.5. Secondary screening
Compounds identified as hits were recovered from NCC library
plates and retested as in the previous screening process using 10 μM in
0.1% DMSO of each compound in biological duplicate with six tech-
nical replicates. Confirmed screening hits included compounds that
exhibited greater than 80% inhibition of parasite growth in the sec-
ondary screening.
2.6. Cellular toxicity assays
To identify false-positive results due to cellular toxicity indirectly
leading to parasite death, the cellular toxicity of confirmed hits was
determined. To do this, assay plates were seeded with approximately
2.5×104 BT cells per well and incubated at 37 °C and 5% CO2 for 24 h.
The growth media of uninfected growing BT host cells was then re-
placed with RPMI containing 10 μM of each compound or 0.1% DMSO
control. Treated BT cells were incubated for an additional 3 days after
which host cell viability was evaluated using CellTiter-Glo®
Luminescent Cell Viability Assay (Promega, USA) according to the
manufacturer's instructions. Compounds that reduced cell viability by 3
standard deviations as compared to DMSO controls were characterized
as toxic and removed from further testing. The 50% toxic concentration
(TC50) for each non-toxic confirmed inhibitory compound was esti-
mated by quantifying cell viability of BT cells incubated with 100, 50,
25, or 12.5 μM for 3 days. The TC50 for each compound was estimated
using a four-parametric logistic function of GraphPad Prism 7.00
Software (GraphPad, USA).
2.7. Half-maximal effective concentration (EC50) calculation
Non-cytotoxic confirmed S. neurona-inhibitory compounds were
purchased for additional testing. Altanserin, chloroxine, diphenylcy-
clopropenone, and pyrimethamine were purchased from Sigma.
Thiothixene and 5-fluorouracil were purchased from AK Scientific.
Perospirone HCl was purchased from Carbosynth. AM-251, artesunate,
azelastine HCl, carmofur, clofazimine, dantrolene, disulfiram, hexa-
chlorophene, perphenazine, prazosin, and primaquine phosphate were
purchased from TargetMol. Purchased chemicals were used to prepare
10mM stock solutions in 100% DMSO. Assay plates seeded with BT
cells and infected with 2.0×104 S. neurona+ GFP/FLUC parasites
were treated with growth media supplemented with 10, 5, 2.5, 1, 0.5,
0.1, and 0.5 μM compound or 0.1% DMSO control. Compounds were
added to assay plates in triplicate and incubated at 37 °C and 5% CO2
for 4 days before measuring FLUC activity as before. Estimation of EC50
value for each compound was accomplished using a four-parametric
logistic function of GraphPad Prism 7.00 Software (GraphPad, USA).
3. Results
3.1. Generation of a clonal FLUC-expressing S. neurona parasite line
To establish a clonal line of S. neurona merozoites expressing GFP
and FLUC without using drug selection, extracellular S. neurona UCD1
parasites were electroporated with pGRA2-GFP/pTUB1-FLUC (Kim
et al., 2007) and transferred to fresh BT cell monolayers for plaque
formation. After the formation of GFP-positive plaques, parasites ex-
pressing the GFP reporter were then isolated from non-expressing
parasites by FACS before cloning by two rounds of limiting dilution.
The resulting 37 potential clones were passaged repeatedly before a
stable S. neurona + GFP/FLUC clone (Fig. 1A) was identified for use in
this screen.
3.2. An accurate and sensitive HTS for S. neurona
Development of a HTS for S. neurona began with optimizing growth
conditions of FLUC-expressing parasites in a multiwell format suitable
for screening. To accurately predict inhibition of parasite growth by
FLUC activity, both growth and inhibition of transgenic parasites was
investigated. The number of S. neurona + GFP/FLUC merozoites used
to inoculate BT host cell monolayers correlated strongly (R2= 0.942)
with the luminescence output reading (Fig. 1B). Additionally, growth
and development of S. neurona+ GFP/FLUC parasites were consistent
with previous observations of S. neurona growth in vitro, with the
completion of one cycle of asexual replication approximately 3 DPI
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(Lindsay et al., 1999). Infection parameters for the HTS were selected
based on the minimal concentration of parasites (2.0× 104 per well)
and time (4 DPI) required to achieve a strong luminescent signal
(Fig. 1C). The rapid decline in FLUC activity observed 5 DPI until the
end of the growth curve was a result of total disruption of the host cell
monolayer by S. neurona + GFP/FLUC parasites (Fig. S1).
Inhibition of S. neurona + GFP/FLUC parasites by pyrimethamine
was demonstrated. Treatment of S. neurona+GFP/FLUC parasites with
10 μM pyrimethamine severely diminished FLUC activity throughout
the 10-day incubation period, which confirmed the utility of the com-
pound as a positive control for the HTS method (Fig. 2A). Inhibition of
S. neurona + GFP/FLUC parasites by pyrimethamine was further
characterized by calculating the EC50 of the compound, which was es-
timated to be 3.22 μM (95% Confidence interval [CI]= 3.06–3.38 μM)
(Fig. 2B). These results are consistent with previous reports that con-
centrations of pyrimethamine greater than or equal to 10 μM were
greater than 95% inhibitory (Lindsay and Dubey, 1999).
To validate the HTS method, the assay's ability to distinguish wells
of microtiter plates treated with a S. neurona-inhibitory compound from
wells treated with DMSO carrier was determined. The robustness of our
HTS method was evaluated by calculating the Z′ statistical parameter
described by Zhang et al. (1999) for three separate validation tests. The
Z′ parameter describes how much of the difference between the means
of sample and control signals is accounted for by the separation band
between the two signals. An ideal assay has a Z′ score greater than 0.5;
however other successful screens have reported lower scores (Bessoff
et al., 2013). The mean Z′ score for the S. neurona HTS was determined
to be 0.637 (Fig. 3) indicating that the assay is highly robust. These
results demonstrate our ability to accurately measure growth and in-
hibition of S. neurona+ GFP/LUC parasites in a method suitable for
HTS of chemical compounds.
3.3. Screen of NCC library
A collection of 725 FDA-approved chemical compounds of the NCC
library were screened against S. neurona + GFP/FLUC parasites using
our validated HTS method. Compounds were screened at 10 μM con-
centration in two separate biological replicates. Results of both screens
are shown as a scatterplot (Fig. 4); the data is also available in Table S1,
XLSX file. Of the compounds tested, 26 exhibited greater than 80%
inhibition in either screen (3.6% hit rate) and were selected for sec-
ondary testing. Twenty-four of the 26 hits from the initial screening
were confirmed by secondary testing (7.7% false-discovery rate). Six of
the 24 confirmed inhibitory compounds exhibited significant host cell
cytotoxicity. Eighteen inhibitory compounds of S. neurona+GFP/FLUC
merozoites were identified from screening the NCC library (Table 1).
Almost all the identified hits were previously unknown inhibitors of S.
neurona. Pyrimethamine was the only compound identified by this
screen that had already been characterized as an inhibitor of S. neurona
growth.
Fig. 1. S. neurona+GFP/FLUC merozoite
growth measured by FLUC activity. (A) S.
neurona + GFP/FLUC parasites infecting BT host
cells, viewed with a Leica confocal fluorescent
microscope (nuclear staining with NucBlue™ Live
ReadyProbes™, bar = 10 μm). (B) Linear re-
lationship between luciferase activity of serially
diluted S. neurona + GFP/FLUC parasites (n = 3
per dilution) after 2 h of infection of BT cells and
parasite concentration (R2= 0.942; 95% CI,
grey). (C) Representative luciferase-based growth
assay of S. neurona + GFP/FLUC parasites in-
fecting BT cells at varying concentrations (n = 3
per concentration).
Fig. 2. Susceptibility of S. neurona+GFP/
FLUC parasites to pyrimethamine measured
by FLUC activity. (A) Measurement of FLUC ac-
tivity of treated (10 μM pyrimethamine, red) or
untreated (0.1% DMSO, blue) S. neurona + GFP/
FLUC merozoites (2.0 × 104 merozoites per well)
in BT cells (three replicates per condition) every
two days for 10 days (DPI, days post-infection).
(B) S. neurona + GFP/FLUC parasites (2.0 × 104
merozoites per well) infecting BT cells were
treated with various concentrations of pyr-
imethamine (0.5–50 μM, n=3 per concentra-
tion) and incubated for 4 DPI before measuring
FLUC activity. (For interpretation of the refer-
ences to colour in this figure legend, the reader is
referred to the Web version of this article.)
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4. Discussion
We successfully prepared, validated, and completed the first cell-
based HTS for S. neurona inhibitors. Our screen identified 18 FDA-ap-
proved compounds from the NCC library with anti-S. neurona activity.
Because the HTS measured a decrease in reporter enzyme activity,
which we have equated to parasite concentration, the specific me-
chanism by which these compounds inhibit S. neurona growth in culture
remains unknown. It is possible that the compounds inhibit S. neurona
by interfering with one or more important stages of in vitro growth
including: attachment, host cell invasion, replication, or egress. These
compounds could be parasiticidal or simply growth inhibitory. More
investigation is required to determine the specific mechanism of in-
hibition of these compounds. Although some of the compounds in the
NCC library have been reported to be inhibitors of S. neurona growth in
vitro, only pyrimethamine was identified by our screen. Neither
trimethoprim, reported to have an EC50 of 2.5 μg/ml (approximately
8.6 μM) for S. neurona parasites in vitro (Lindsay and Dubey, 1999), nor
nitazoxanide, with a reported mean 90% inhibitory activity against S.
neurona of 1.9mg/L (approximately 6.2 μM) (Gargala et al., 2009),
were found to be greater than 80% inhibitory in this screen. This un-
expected result may be explained by variation in assay methods and/or
strain differences. Repeated testing of trimethoprim and nitazoxanide
estimated EC50 values to be approximately 19 μM and 12 μM respec-
tively, both of which are greater than the 10 μM used in the screening
assay (data not shown).
We also identified several potential growth-enhancing compounds
of S. neurona reflected by increases in FLUC activity. Possible ex-
planations for these results include: compound treatment increases
available resources for parasite growth by inhibiting host cell pro-
liferation or nutrient uptake (i.e., albendazole and thibendazole),
treatment increases intracellular ionic composition in host cells for
parasite use by frequent channel opening (i.e., zolpidem tartrate), or
compounds help stabilize and/or activate the FLUC enzyme in-
dependent of effects on either host cells or parasites. Although these
results were not confirmed with secondary screening, future in-
vestigation into the effect these compounds have of S. neurona may
provide valuable insight into host cell factors that support parasite
growth.
Many of the inhibitory compounds identified in this screen have
well-defined mechanisms of action, which may assist in the discovery of
important biologic processes required for S. neurona infection and in-
tracellular survival. For example, we found many of the inhibitory
compounds to have activity against dopamine and/or serotonin re-
ceptors. For example, identification of altanserin, a 5-hydro-
xytryptamine receptor 2 A (5-HT2A) antagonist, as an S. neurona in-
hibitor, suggests that host cell serotonin signaling may play a role in the
asexual reproduction of S. neurona parasites. Additionally, the con-
firmed inhibitory compounds altanserin, azelastine HCl, chloroxine,
disulfiram, hexachlorophene, perphenazine, prazosin, and primaquine
phosphate all have reported dopamine receptor activity. We anticipated
many screening hits to have dopamine receptor activity because of the
high concentration (20%; 148/725) of active compounds in the NCC
library. However, almost half of confirmed inhibitory compounds
(44%; 8/18) have evidence of dopamine receptor activity. This en-
richment of compounds with dopamine receptor activity in the
screening results highlights the potential importance of host cell do-
pamine signaling in S. neurona growth. Alternatively, dopamine re-
ceptor inhibitors may cross react with an unknown target in Sarcocystis.
All the inhibitory compounds identified in this screen are FDA-ap-
proved, yet only a few have prescribed use in animals. Dantrolene, the
most effective compound against S. neuronamerozoites in this screen, is
a direct acting muscle relaxant used in the prevention and treatment of
equine post-anesthetic myositis and equine exertional rhabdomyolysis
(Edwards et al., 2003). Use of dantrolene to prevent ‘tying up’ of ex-
ercising horses on the racetrack is common, however this compound is
regulated by the Association of Racing Commissioners International
and a withdrawal period is required to prevent a positive test. Phar-
macokinetic analysis of dantrolene in eight healthy horses estimated
the peak plasma concentration for dantrolene dose to be 28.9 ± 21.6
(85.95 nM ± 64.24 nM) and 37.8 ± 12.8 (112.4 nM ± 38.07 nM)
ng/mL for 500mg capsules and paste respectively, which occurred at
3.8 h after administration for both formulations (DiMaio Knych et al.,
2011). The plasma concentration of dantrolene needed to reach the
EC50 concentration for S. neurona inhibition (21.9 ng/ml or 65 nM,
Table 1) suggests that this compound could be a potential new therapy
for EPM. However, a successful EPM treatment needs to penetrate the
CNS of infected animals as S. neurona parasites are found in the CNS in
the clinical presentation of horses with EPM. Although there has been
controversy as to whether dantrolene can easily penetrate the blood
brain barrier and enter the CNS of treated animals, dantrolene has been
shown to penetrate the CNS in both primate (Wuis et al., 1989) and
Fig. 3. Developed HTS accurately identifies wells treated with an inhibitor of S.
neurona growth. S. neurona + GFP/FLUC parasites infecting BT cells (2.0 × 104 mer-
ozoites per well) in three 96-well plates were randomly treated with either 10 μM pyr-
imethamine (n= 12 per plate, red) or 0.1% DMSO carrier control (n= 60 per plate,
blue). Uninfected BT cells were included as a negative control (n= 24 per plate, black).
Infected and uninfected cells were incubated at 37 °C and 5% CO2 for 4 days before
measuring FLUC activity. The sample measurements (i.e., 96 wells per plate) for each
biological replicate are separated by vertical dashed lines. The Z′ score for each replicate
was calculated using FLUC activity of DMSO-treated parasites (horizontal dashed lines, 3
S.D. below normalized untreated mean) and uninfected BT cells (equation (2)). (For in-
terpretation of the references to colour in this figure legend, the reader is referred to the
Web version of this article.)
Fig. 4. HTS identifies compounds of NCC library that inhibit S. neurona growth.
Screening data from two independent screens of NCC library. Open triangles indicate
compounds with host-cell toxicity. The horizontal dotted line represents the 80% in-
hibition cut-off for selecting screening ‘hits’ (red) from non-inhibitory compounds (blue).
Known inhibitory compound pyrimethamine included as positive control (green). (For
interpretation of the references to colour in this figure legend, the reader is referred to the
Web version of this article.)
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murine (Wei and Perry, 1996; Chen et al., 2008; Enokizono et al., 2008;
Peng et al., 2012) models. The ability of dantrolene to penetrate the
CNS of treated horses has yet to be determined. Dantrolene binds to
calcium receptors in muscle fiber and interferes with excitation-con-
traction coupling. We hypothesize that the disruption of intracellular
calcium by dantrolene possibly inhibits the life cycle of S. neurona
merozoites by disrupting the function of crucial parasite calcium-de-
pendent protein kinases (CDPKs). Apicomplexan parasites contain a
diverse family of CDPKs that are involved in many cellular pathways
including attachment, invasion, and egress. Genomic studies have
identified 8 orthologs of S. neurona CDPKs in T. gondii including
TgCDPK1 (Murungi and Kariithi, 2017). Inhibition of TgCDPK1 disrupts
host cell invasion and egress of Toxoplasma parasites (Lourido et al.,
2010).
We also sought to identify inhibitory compounds of S. neurona with
inhibitory action against other related apicomplexan parasites. The
NCC library is publicly available and has been used in a similar HTS
method to identify inhibitors of Cryptosporidium parvum (Bessoff et al.,
2013). Additionally, many of the compounds in the NCC library were
included in a drug-repurposing HTS of T. gondii (Dittmar et al., 2016)
and various anti-Plasmodium falciparum testing. Searching the PubChem
BioAssay database (Wang et al., 2017) for biological activity of NCC
library compounds against P. falciparum and T. gondii revealed many
additional inhibitory compounds of these parasites. We also completed
a preliminary screen of confirmed inhibitory compounds of S. neurona
with no available data against FLUC expressing T. gondii (Bowden,
unpublished data). All NCC library compounds with available activity
data against P. falciparum (123/725 compounds) were identified as
inhibitors of P. falciparum growth. Of the compounds with activity data
against T. gondii (127/725 compounds), only 22 compounds of the NCC
library are classified as inhibitors of parasite growth. In comparing the
activity data of library compounds against apicomplexan parasites
(Fig. 5), we found only carmofur and 5-fluorouracil to be active against
all four parasites; the data is also available in Table S2, XLSX file.
Carmofur is a derivative of 5-fluorouracil and both compounds are
nucleotide analogs commonly used as chemotherapies. Currently, to-
pical 5-fluorouracil is used to treat squamous cell carcinoma, mela-
noma, and sarcoids of horses. However, due to the cellular toxicity of
both carmofur and 5-fluorouracil, these compounds could not be used
as a treatment for EPM. Interestingly, almost all inhibitory compounds
of S. neurona identified in this screen (15/18; 83%) had activity against
at least one parasite considered in this comparison. It is possible that
the remaining inhibitory compounds are not actually unique to S.
neurona, as the activity data for all the NCC library compounds against
T. gondii and P. falciparum in this comparison were not available.
The HTS method developed and validated in this work has the po-
tential to improve the way drug compounds for treatment of EPM are
identified and verified in vitro prior to in vivo trials in available murine
models (Witonsky et al., 2005; Dubey et al., 2013) and clinical trials in
horses. This advancement employs the current technologies available
for drug discovery, and has aided in the identification of novel ther-
apeutic agents for EPM. We identified several compounds in this screen
that demonstrated greater S. neurona inhibition in vitro at lower con-
centrations than compounds which are currently being used to treat
EPM. Certainly, a targeted screen of related chemical compounds, for
example inhibitors of CDPKs (Ojo et al., 2016; Hulverson et al., 2017)
would yield additional insight into S. neurona biology.
Beyond similarities to other apicomplexan parasites, little is known
about critical biologic processes in S. neurona. Genomic studies have
identified conservation of attachment and invasion machinery between
T. gondii and S. neurona, yet substantial differences between the two
parasites remain (Blazejewski et al., 2015). For example, T. gondii uses
an expanded repertoire of effector proteins (e.g., microneme, rhoptry,
dense granule) to modulate host cell processes and evade immune de-
tection while residing in a parasitophorous vacuole in the host cell,
whereas S. neurona lacks many important effector proteins, rhoptries
(secretory organelles), and forgoes the development of a para-
sitophorous vacuole during invasion and intracellular growth. Future
investigation into defining the specific mechanism of action of the most
promising inhibitory compounds identified by our screen, and in vivo
Table 1
Inhibitory compounds of S. neurona.
Compound Name PubChem CID Description EC50 in μM (95% CI) TC50 in μM TI (TC50/EC50)
Altanserin 23581819 5-HT2A-R antagonist 3.5 (2.6–4.5) > 100 a 29
AM-251 2125 CB1 antagonist 1.7 (1.4–2.0) > 100 59
Artesunate 65664 Antimalarial 3.3 (2.8–3.9) > 100 30
Azelastine HCl 54360 H1-R antagonist 2.5 (2.0–3.0) 28 11
Carmofur 2577 Nucleotide analog 0.73 (0.65–0.81) > 100 137
Chloroxine 2722 Antibacterial 2.5 (2.2–2.8) 16 6
Clofazimine 2794 Antibacterial 3.7 (3.2–4.2) > 100 27
Dantrolene 6604100 Channel inhibitor 0.065 (0.036–0.12) 52 800
Diphenylcyclopropenone 65057 Immunomodulator 2.5 (1.2–5.4) 19 8
Disulfiram 3117 ALDH inhibitor 0.15 (0.074–0.31) 20 133
Fluorouracil 3385 Nucleotide analog 0.79 (0.75–0.83) 78 99
Hexachlorophene 3598 Antibacterial 2.8 (2.2–3.6) 56 20
Perospirone HCl 115367 Dopamine-R antagonist 3.4 (2.6–4.2) 86 25
Perphenazine 4748 Dopamine-R antagonist 3.3 (2.8–3.8) 14 4
Prazosin 19846442 Andrenergic α1-R antagonist 6.0 (4.1–7.8) 45 8
Primaquine phosphate 359247 Antimalarial 2.2 (1.7–2.6) 47 21
Pyrimethamine 4993 DHFR inhibitor 3.9 (3.6–4.2) > 100 26
Thiothixene 941651 Dopamine-R antagonist 6.3 (3.2–9.3) 30 5
a Maximum compound concentration tested.
Fig. 5. Comparison of activity of NCC compounds against apicomplexan parasites.
Number of compounds with shared inhibitory activity against one or more apicomplexan
parasite listed in diagram. The total number of compounds of the NCC library (725
compounds total) with available activity data against each parasite is shown in par-
entheses below the parasite name.
G.D. Bowden et al. IJP: Drugs and Drug Resistance 8 (2018) 137–144
142
confirmatory studies are required. This information will aid in char-
acterizing important and potentially unique pathway(s) and/or target
(s) within S. neurona for the development of a novel drugs for EPM.
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